For multiple myeloma, CAR-T cells targeting B cell maturation antigen (BCMA) show initial efficacy, but relapses are common, with a median progression-free survival of 11.8 months in one study [25]. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.